- Home
- OSUR vs ZBIO Comparison
OSUR vs ZBIO Comparison
Compare OSUR & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- ZBIO
- Stock Information
- Founded
- OSUR 2000
- ZBIO 2019
- Country
- OSUR United States
- ZBIO United States
- Employees
- OSUR N/A
- ZBIO N/A
- Industry
- OSUR Medical/Dental Instruments
- ZBIO
- Sector
- OSUR Health Care
- ZBIO
- Exchange
- OSUR Nasdaq
- ZBIO NYSE
- Market Cap
- OSUR 266.7M
- ZBIO 268.7M
- IPO Year
- OSUR 1986
- ZBIO 2024
- Fundamental
- Price
- OSUR $3.46
- ZBIO $7.90
- Analyst Decision
- OSUR Hold
- ZBIO Strong Buy
- Analyst Count
- OSUR 2
- ZBIO 6
- Target Price
- OSUR $5.50
- ZBIO $31.83
- AVG Volume (30 Days)
- OSUR 1.0M
- ZBIO 130.1K
- Earning Date
- OSUR 05-07-2025
- ZBIO 03-25-2025
- Dividend Yield
- OSUR N/A
- ZBIO N/A
- EPS Growth
- OSUR N/A
- ZBIO N/A
- EPS
- OSUR N/A
- ZBIO N/A
- Revenue
- OSUR $185,827,000.00
- ZBIO $5,000,000.00
- Revenue This Year
- OSUR N/A
- ZBIO N/A
- Revenue Next Year
- OSUR $8.41
- ZBIO N/A
- P/E Ratio
- OSUR N/A
- ZBIO N/A
- Revenue Growth
- OSUR N/A
- ZBIO N/A
- 52 Week Low
- OSUR $2.69
- ZBIO $5.83
- 52 Week High
- OSUR $6.83
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- OSUR 46.38
- ZBIO N/A
- Support Level
- OSUR $3.34
- ZBIO N/A
- Resistance Level
- OSUR $3.64
- ZBIO N/A
- Average True Range (ATR)
- OSUR 0.18
- ZBIO 0.00
- MACD
- OSUR 0.02
- ZBIO 0.00
- Stochastic Oscillator
- OSUR 62.12
- ZBIO 0.00
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.